Rachel B Salit

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4340173/publications.pdf

Version: 2024-02-01

		1040056	888059
18	636	9	17
papers	citations	h-index	g-index
1.0	1.0	1.0	1166
18	18	18	1166
all docs	docs citations	times ranked	citing authors

o

#	Article	IF	Citations
1	Cord-Blood Transplantation in Patients with Minimal Residual Disease. New England Journal of Medicine, 2016, 375, 944-953.	27.0	352
2	Hematopoietic Cell Transplantation for Myelofibrosis: the Dynamic International Prognostic Scoring System Plus Risk Predicts Post-Transplant Outcomes. Biology of Blood and Marrow Transplantation, 2018, 24, 386-392.	2.0	52
3	Success of Immunosuppressive Treatments in Patients with Chronic Graft-versus-Host Disease. Biology of Blood and Marrow Transplantation, 2018, 24, 555-562.	2.0	50
4	Pre-hematopoietic cell transplant Ruxolitinib in patients with primary and secondary myelofibrosis. Bone Marrow Transplantation, 2020, 55, 70-76.	2.4	39
5	Rates and Risk Factors for Post-Traumatic Stress Disorder Symptomatology among Adult Hematopoietic Cell Transplant Recipients and Their Informal Caregivers. Biology of Blood and Marrow Transplantation, 2019, 25, 145-150.	2.0	28
6	Prognostic Performance of the Augmented Hematopoietic Cell Transplantation-Specific Comorbidity/Age Index in Recipients of Allogeneic Hematopoietic Stem Cell Transplantation from Alternative Graft Sources. Biology of Blood and Marrow Transplantation, 2019, 25, 1045-1052.	2.0	19
7	Transplant Conditioning with Treosulfan/Fludarabine with or without Total Body Irradiation: A Randomized Phase II Trial in Patients with Myelodysplastic Syndrome and Acute Myeloid Leukemia. Biology of Blood and Marrow Transplantation, 2018, 24, 956-963.	2.0	18
8	Prognostic Value of the Hematopoietic Cell Transplantation Comorbidity Index for Patients Undergoing Reduced-Intensity Conditioning Cord Blood Transplantation. Biology of Blood and Marrow Transplantation, 2017, 23, 654-658.	2.0	14
9	Early Mixed Lymphoid Donor/Host Chimerism is Associated with Improved Transplant Outcome in Patients with Primary or Secondary Myelofibrosis. Biology of Blood and Marrow Transplantation, 2020, 26, 2197-2203.	2.0	12
10	Treosulfan-based conditioning is feasible and effective for cord blood recipients: a phase 2 multicenter study. Blood Advances, 2020, 4, 3302-3310.	5.2	11
11	Targeted Sequencing Improves DIPSS-Plus Prognostic Scoring in Myelofibrosis Patients Undergoing Allogeneic Transplantation. Biology of Blood and Marrow Transplantation, 2020, 26, 1371-1374.	2.0	9
12	Outcomes of Cord Blood Transplantation as Salvage TherapyÂafter Graft Failure or Relapse after Prior AllogeneicÂTransplantation. Biology of Blood and Marrow Transplantation, 2016, 22, 339-343.	2.0	8
13	Return-to-Work Guidelines and Programs for Post-Hematopoietic Cell Transplantation Survivors: An Initial Survey. Biology of Blood and Marrow Transplantation, 2020, 26, 1520-1526.	2.0	7
14	Role of Hematopoietic Stem Cell Transplantation in Patients with Myeloproliferative Disease. Hematology/Oncology Clinics of North America, 2014, 28, 1023-1035.	2.2	6
15	Diagnosis of pulmonary hypertension by noninvasive methods in hematopoietic cell transplant patients with myelofibrosis. Bone Marrow Transplantation, 2020, 55, 1681-1683.	2.4	4
16	Impact of Center Experience with Donor Type on Outcomes: A Secondary Analysis, Blood and Marrow Transplant Clinical Trials Network 1101Open for Accrual June 2012Open for Accrual June 2012. Transplantation and Cellular Therapy, 2022, 28, 406.e1-406.e6.	1.2	4
17	The role of JAK inhibitors in hematopoietic cell transplantation. Bone Marrow Transplantation, 2022, 57, 857-865.	2.4	3

18

 $He matopoietic \ Cell\ Transplant\ for\ Myelofibrosis.\ , 2021,\ , 311-327.$